il 17a antagonist 3

IL-17A antagonist 3 is an inhibitor of IL-17A.

IL-17 modulator 4 is a prodrug of IL-17 modulator 1, which is an efficacious modulator of IL-17.

6-[(3S,8S,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxo-1H-pyridine-3,4-dicarbonitrile is a biologically active compound, which is utilized for research in the fields of chemistry and life sciences.

TRPM8 antagonist WS-3 (Cyclohexanecarboxamide) is an agonist of TRPM8( EC50 : 3.7 μM).

5-HT3 antagonist 3 (Compound 15b) is a high-affinity 5-HT3 receptor antagonist that binds to 5-HT3 receptors in rat brain cortical membranes (Ki: 0.25 nM).

AMPA receptor antagonist-3 is an AMPA receptor antagonist.

IL-17A inhibitor 1 is a IL-17A inhibitor with IC50 of <9.45 nM in alphalisa assay. IL-17A inhibitor 1 inhibits HT-29 cells with IC50 of 9.3 nM.

Sigma-1 receptor antagonist 3 is a potent and selective antagonist of Sigma-1 (σ1) receptor(Ki : 1.14 nM), has the potential for the neuropathic pain.

CCR2 antagonist 3 (AZD-2927) is an antagonist of CCR2.

TRPM8 antagonist 3 is a blocker of TRPM8 (IC50 = 11 nM).

LPA5 antagonist 3 (Example 74), a lysophosphatidic acid receptor 5 (LPA5) antagonist, exhibits potent activity with an IC50 value of 170 nM. It is primarily utilized in the research of pain disorders and atherosclerosis [1].

Compound 24e, a leukotriene B4 (LTB4) antagonist, exhibits an inhibitory concentration 50 (IC50) of 477 nM and demonstrates anti-inflammatory activity [1].

Calcium Channel antagonist 3 is a voltage-gated calcium channel inhibitor (IC50 : 5-20 μM).

Compound 5e, a GPR34 receptor antagonist, exhibits selective inhibition of lysophosphatidylserine-induced ERK1 2 phosphorylation in a dose-dependent manner, demonstrating an IC50 value of 0.680 μM without significant cytotoxicity. Additionally, it displays antisensory activity in a mouse neuropathic pain model [1].

EP3 antagonist 3 (compound 2) is a potent and specific EP3 receptor antagonist with a significant pKi value of 8.3, high oral bioavailability, and excellent pharmacokinetic properties, making it ideal for experimental overactive bladder (OAB) research [1].

TRPV4 antagonist 3 is a TRPV4 antagonist (pIC50 = 8.4).

IL-17A Modulator-3, an inhibitor of IL-17A/A, exhibits an IC 50 value of less than 10 μM. It is utilized in research related to inflammation, cancer, and autoimmune diseases.

Adenosine receptor antagonist 3 has the potential for cancer disease research which is a potent adenosine receptor antagonist [1].

Mu opioid receptor antagonist 3 (compound 26) is a potent and selective MOR antagonist with the ability to penetrate the blood-brain barrier (Ki: 0.24 nM, EC50: 0.54 nM). This compound can be used to study opioid use disorder (OUD).

A1AR antagonist 3 (compound 13) is a selective adenylate 1 (A1) receptor antagonist with an affinity for human A1 (Ki: 9.69 nM) and rat A1 (Ki: 0.529 nM). It is suitable for research on neurological diseases.

Androgen receptor antagonist 3 (Compound C18) exhibits anticancer activity as an antagonist of the androgen receptor (AR) with an IC50 value of 2.4 μM [1].

GPR84 Antagonist 3 (compound 42), a potent inhibitor of the G-protein-coupled receptor 84 (GPR84), exhibits a pIC50 value of 8.28, indicating strong antagonistic activity by inhibiting GTPγS. Additionally, it possesses a favorable pharmacokinetic profile, suitable for further research and development [1].

GPVI antagonist 3 (Compound 2) is a promising antiplatelet agent that selectively inhibits the interaction between the Glycoprotein VI (GPVI) receptor and its ligands. It demonstrates potent inhibitory effects with IC50 values of 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin, and 51.74 μM for thrombin, positioning it as a potential novel antithrombotic treatment [1].

17-hydroxyestr-4-en-3-one is a useful organic compound for research related to life sciences and the catalog number is T131631.

IL-17 modulator 3 (US20200247785A1) is a chemical compound that acts as an IL-17 modulator. It has potential applications in researching inflammation, cancer, and autoimmune diseases.

Estrogen receptor antagonist 3 is a potent degradation agent of the estrogen receptor (ER). Estrogen signaling systems regulate cell growth, differentiation, and apoptosis, and estrogen receptor antagonist 4 has shown potential for cancer research.

Hop-17(21)-en-3-ol is a natural product of Gentiana, Gentianaceae. The catalog number is TN4225 and the CAS number is 564-14-7. Hop-17(21)-en-3-ol can be used as a reference standard.

ent-3-Oxokauran-17-oic acid is a natural product for research related to life sciences. The catalog number is TN3945 and the CAS number is 151561-88-5.

CXCR4 antagonist 3 (compound 12a), an effective antagonist of CXCR4, exhibits an IC50 of 11 nM. It is a congener of TIQ15, showcasing exceptional properties such as CXCR4 antagonism, CYP 2D6 inhibition, metabolic stability, and permeability. With its potential for research on the human immunodeficiency virus, CXCR4 antagonist 3 holds great promise [1].

(R)-Methyl 4-((3R,5S,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate is a useful organic compound for research related to life sciences. The catalog number is T66656 and the CAS number is 10538-59-7.

EP4 receptor antagonist 3 is a highly potent and specific inhibitor of the EP4 receptor, intended for research purposes in studying EP4 receptor-mediated diseases, including acute and chronic pain, osteoarthritis, rheumatoid arthritis, and cancer.

TRPA1 Antagonist 3 is a compound with photoswitchable properties that acts as an agonist on the TRPA1 channel, providing the ability for optical control.

IL-17 Modulator 1 (disodium) is a potent, orally active compound, known for its high efficacy in modulating IL-17. This compound is extensively utilized for researching various diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis[1].

IL-17 modulator 5 is a IL-17 inhibitor, with an IC 50 of 1 nM .

IL-17A modulator-2, exhibits inhibitory properties towards IL-17A, with a pIC50 of 8.3. Its effectiveness lies in attenuating the biological effects associated with IL-17A activity. IL-17A modulator-2 finds utility in the study of diseases and disorders characterized by dysregulated IL-17A modulation, such as those involving immune dysfunction, autoimmune pathology, cancer, and neurodegenerative conditions.

OT antagonist 3 is an antagonist of oxytocin (OT).

Compound 159, an IL-17 modulator 2, is an orally active modulator of IL-17 that significantly reduces IL-6, IFN-γ, and edema, and can be used in arthritis studies [1].

IL-17 Modulator 9 (compound 453) is an orally active agent that modulates IL-17. It notably diminishes levels of IL-6, IFN-γ, and edema, making it useful for studying inflammation [1].

IL-17 Modulator 8 (compound 286) is an orally active agent that modulates IL-17. It notably diminishes levels of IL-6, IFN-γ, and edema. IL-17 Modulator 8 is applicable for use in arthritis research [1].

SSTR5 antagonist 3 (Compound 23) serves as a potent somatostatin receptor subtype 5 (SSTR5) antagonist, demonstrating oral activity and minimal hERG inhibition. It shows significant efficacy, with IC50 values of 2.8 nM in humans and 1.4 nM in mice. This compound is utilized in gallstone research [1].

TRPV1 antagonist 3 (Compound 7q) is a highly potent TRPV1 receptor antagonist with an IC50 of 2.66 nM against capsaicin. It exhibits selectivity in its mode of action, is orally bioavailable (60%), and can penetrate the central nervous system [1].

ET receptor antagonist 3 (compound 17d) is an orally active ET receptor antagonist with an IC50 of 0.26 nM, utilized for pulmonary arterial hypertension (PAH) research. This compound demonstrates efficacy in mitigating monocrotaline-induced PAH in a rat model [1].

CCR4 antagonist 3 hydrochloride is an orally active, potent and selective CCR4 antagonist. CCR4 antagonist 3, featuring a novel piperidinyl-azetidine motif, has IC 50 s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4 antagonist 3 has antitumor activity.

IL-17A antagonist 1 is an IL-17A antagonist for the study of interleukin-related inflammatory and immune diseases.

(3S,8S,9S,10R,13R,14S,17R)-10,13-Dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl (Z)-octadec-9-en-1-yl carbonate is a useful organic compound for research related to life sciences. The catalog number is T65075 and the CAS number is 17110-51-9.

P2X7 receptor antagonist-3 is a potent inhibitor of the P2X7 receptor, with IC50 values of 4.2 nM in humans and 6.8 nM in rats, demonstrating its high efficacy across species.

3-(acetyloxy)androstane-17-carboxylic acid is a useful organic compound for research related to life sciences and the catalog number is T131438.